Moderna previously said it would exclude people with HIV from its trial. But the drugmaker tweeted Aug. 5 that it is “committed to working with all communities who could benefit from our Covid-19 vaccine” and added those with “controlled HIV who are not otherwise immunosuppressed” to the clinical trial protocols.
Advocates are petitioning Pfizer to do the same with its experimental COVID-19 vaccine, Bloomberg reported.
Including people with HIV in vaccine trials can help researchers understand how well the vaccine works for those with HIV as well as side effects they pose. About 1.2 million people in the U.S. have HIV.
Read the full article here.
More articles on pharmacy:
Pfizer inks deal with Gilead to manufacture remdevisir for COVID-19 patients
Researchers struggling to enroll minority groups in COVID-19 vaccine trials
Eli Lilly drug first in series to be studied as coronavirus treatment by NIH
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.